These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

228 related articles for article (PubMed ID: 38087316)

  • 1. Predicting positron emission tomography brain amyloid positivity using interpretable machine learning models with wearable sensor data and lifestyle factors.
    Kimura N; Aota T; Aso Y; Yabuuchi K; Sasaki K; Masuda T; Eguchi A; Maeda Y; Aoshima K; Matsubara E
    Alzheimers Res Ther; 2023 Dec; 15(1):212. PubMed ID: 38087316
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association of Modifiable Lifestyle Factors With Cortical Amyloid Burden and Cerebral Glucose Metabolism in Older Adults With Mild Cognitive Impairment.
    Kimura N; Aso Y; Yabuuchi K; Ishibashi M; Hori D; Sasaki Y; Nakamichi A; Uesugi S; Jikumaru M; Sumi K; Eguchi A; Obara H; Kakuma T; Matsubara E
    JAMA Netw Open; 2020 Jun; 3(6):e205719. PubMed ID: 32515796
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effect of amyloid on memory and non-memory decline from preclinical to clinical Alzheimer's disease.
    Lim YY; Maruff P; Pietrzak RH; Ames D; Ellis KA; Harrington K; Lautenschlager NT; Szoeke C; Martins RN; Masters CL; Villemagne VL; Rowe CC;
    Brain; 2014 Jan; 137(Pt 1):221-31. PubMed ID: 24176981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predicting Amyloid-β Levels in Amnestic Mild Cognitive Impairment Using Machine Learning Techniques.
    Ezzati A; Harvey DJ; Habeck C; Golzar A; Qureshi IA; Zammit AR; Hyun J; Truelove-Hill M; Hall CB; Davatzikos C; Lipton RB;
    J Alzheimers Dis; 2020; 73(3):1211-1219. PubMed ID: 31884486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive and neuroimaging features and brain β-amyloidosis in individuals at risk of Alzheimer's disease (INSIGHT-preAD): a longitudinal observational study.
    Dubois B; Epelbaum S; Nyasse F; Bakardjian H; Gagliardi G; Uspenskaya O; Houot M; Lista S; Cacciamani F; Potier MC; Bertrand A; Lamari F; Benali H; Mangin JF; Colliot O; Genthon R; Habert MO; Hampel H;
    Lancet Neurol; 2018 Apr; 17(4):335-346. PubMed ID: 29500152
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Machine Learning for the Prediction of Amyloid Positivity in Amnestic Mild Cognitive Impairment.
    Kang SH; Cheon BK; Kim JS; Jang H; Kim HJ; Park KW; Noh Y; Lee JS; Ye BS; Na DL; Lee H; Seo SW
    J Alzheimers Dis; 2021; 80(1):143-157. PubMed ID: 33523003
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Predicting Amyloid Burden to Accelerate Recruitment of Secondary Prevention Clinical Trials.
    Langford O; Raman R; Sperling RA; Cummings J; Sun CK; Jimenez-Maggiora G; Aisen PS; Donohue MC
    J Prev Alzheimers Dis; 2020; 7(4):213-218. PubMed ID: 32920622
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
    Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
    Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The combination of apolipoprotein E4, age and Alzheimer's Disease Assessment Scale - Cognitive Subscale improves the prediction of amyloid positron emission tomography status in clinically diagnosed mild cognitive impairment.
    Ba M; Ng KP; Gao X; Kong M; Guan L; Yu L;
    Eur J Neurol; 2019 May; 26(5):733-e53. PubMed ID: 30561868
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasma Aβ42/40 ratio alone or combined with FDG-PET can accurately predict amyloid-PET positivity: a cross-sectional analysis from the AB255 Study.
    Pérez-Grijalba V; Arbizu J; Romero J; Prieto E; Pesini P; Sarasa L; Guillen F; Monleón I; San-José I; Martínez-Lage P; Munuera J; Hernández I; Buendía M; Sotolongo-Grau O; Alegret M; Ruiz A; Tárraga L; Boada M; Sarasa M;
    Alzheimers Res Ther; 2019 Dec; 11(1):96. PubMed ID: 31787105
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of Longitudinal β-Amyloid Accumulation Determined by Positron Emission Tomography With Clinical and Cognitive Decline in Adults With Probable Lewy Body Dementia.
    Nedelska Z; Schwarz CG; Lesnick TG; Boeve BF; Przybelski SA; Lowe VJ; Kremers WK; Gunter JL; Senjem ML; Graff-Radford J; Ferman TJ; Fields JA; Knopman DS; Petersen RC; Jack CR; Kantarci K
    JAMA Netw Open; 2019 Dec; 2(12):e1916439. PubMed ID: 31790563
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Machine Learning Model to Predict Diagnosis of Mild Cognitive Impairment by Using Radiomic and Amyloid Brain PET.
    Ciarmiello A; Giovannini E; Pastorino S; Ferrando O; Foppiano F; Mannironi A; Tartaglione A; Giovacchini G;
    Clin Nucl Med; 2023 Jan; 48(1):1-7. PubMed ID: 36240660
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of Brain Amyloid Deposition and Cortical Glucose Metabolism Between Clinic- and Community-Based Cohort.
    Yabuuchi K; Kimura N; Masuda T; Matsubara E
    J Alzheimers Dis; 2023; 95(1):299-306. PubMed ID: 37483008
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Subcortical and Cortical Regions of Amyloid-β Pathology Measured by 11C-PiB PET Are Differentially Associated with Cognitive Functions and Stages of Disease in Memory Clinic Patients.
    Almkvist O; Brüggen K; Nordberg A
    J Alzheimers Dis; 2021; 81(4):1613-1624. PubMed ID: 33967046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Association of Factors With Elevated Amyloid Burden in Clinically Normal Older Individuals.
    Sperling RA; Donohue MC; Raman R; Sun CK; Yaari R; Holdridge K; Siemers E; Johnson KA; Aisen PS;
    JAMA Neurol; 2020 Jun; 77(6):735-745. PubMed ID: 32250387
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Memory self-awareness in the preclinical and prodromal stages of Alzheimer's disease.
    Vannini P; Amariglio R; Hanseeuw B; Johnson KA; McLaren DG; Chhatwal J; Pascual-Leone A; Rentz D; Sperling RA
    Neuropsychologia; 2017 May; 99():343-349. PubMed ID: 28385579
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Cross-Validation of FDG- and Amyloid-PET Biomarkers in Mild Cognitive Impairment for the Risk Prediction to Dementia due to Alzheimer's Disease in a Clinical Setting.
    Iaccarino L; Chiotis K; Alongi P; Almkvist O; Wall A; Cerami C; Bettinardi V; Gianolli L; Nordberg A; Perani D
    J Alzheimers Dis; 2017; 59(2):603-614. PubMed ID: 28671117
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Effect of Early vs Late Amyloid Positron Emission Tomography in Memory Clinic Patients: The AMYPAD-DPMS Randomized Clinical Trial.
    Altomare D; Barkhof F; Caprioglio C; Collij LE; Scheltens P; Lopes Alves I; Bouwman F; Berkhof J; van Maurik IS; Garibotto V; Moro C; Delrieu J; Payoux P; Saint-Aubert L; Hitzel A; Molinuevo JL; Grau-Rivera O; Gispert JD; Drzezga A; Jessen F; Zeyen P; Nordberg A; Savitcheva I; Jelic V; Walker Z; Edison P; Demonet JF; Gismondi R; Farrar G; Stephens AW; Frisoni GB;
    JAMA Neurol; 2023 Jun; 80(6):548-557. PubMed ID: 37155177
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Amyloid and tau imaging biomarkers explain cognitive decline from late middle-age.
    Betthauser TJ; Koscik RL; Jonaitis EM; Allison SL; Cody KA; Erickson CM; Rowley HA; Stone CK; Mueller KD; Clark LR; Carlsson CM; Chin NA; Asthana S; Christian BT; Johnson SC
    Brain; 2020 Jan; 143(1):320-335. PubMed ID: 31886494
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.